Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01492361
Other study ID # AMR-01-01-0019
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 2011
Est. completion date May 2018

Study information

Verified date March 2022
Source Amarin Pharma Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc. for the treatment of cardiovascular disease in statin-treated patients with hypertriglyceridemia. The purpose of this study was to evaluate whether this drug, combined with a statin therapy, will be superior to the statin therapy alone, when used as a prevention in reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia.


Recruitment information / eligibility

Status Completed
Enrollment 8179
Est. completion date May 2018
Est. primary completion date May 2018
Accepts healthy volunteers No
Gender All
Age group 45 Years and older
Eligibility Inclusion Criteria: - Men and non-pregnant or sterile women ages 45 and older - Hypertriglyceridemia - On statin therapy for at least four weeks - Either having established cardiovascular disease or at high risk for cardiovascular disease Exclusion Criteria: - Severe heart failure - Any life-threatening disease other than cardiovascular disease - Active severe liver disease - Hemoglobin A1c >10.0% - Poorly controlled hypertension - Planned coronary intervention (such as stent placement or heart bypass) or any non-cardiac major surgical procedure - Known familial lipoprotein lipase deficiency (Fredrickson Type I), apolipoprotein C-II deficiency, or familial dysbetalipoproteinemia (Fredrickson Type III) - Known hypersensitivity to the study product, fish and/or shellfish, or placebo - History of acute or chronic pancreatitis - Patients are excluded if using the following medications: - PCSK9 inhibitors - niacin >200 mg/day or fibrates; - any omega-3 fatty acid medications ; - dietary supplements containing omega-3 fatty acids (e.g., flaxseed oil, fish oil, krill oil, or algal oil); - bile acid sequestrants

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AMR101
Parallel Assignment
Placebo
Parallel Assignment
Statin therapy
Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C >40 mg/dL and =100 mg/dL)

Locations

Country Name City State
Australia Amarin Investigational Site Bedford Park South Australia
Australia Amarin Investigational Site Brisbane Queensland
Australia Amarin Investigational Site Camperdown New South Wales
Australia Amarin Investigational Site Chermside Queensland
Australia Amarin Investigational Site Fitzroy Victoria
Australia Amarin Investigational Site Fremantle Western Australia
Australia Amarin Investigational Site Geelong Victoria
Australia Amarin Investigational Site Heidelberg Heights Victoria
Australia Amarin Investigational Site Joondalup Western Australia
Australia Amarin Investigational Site Launceston Tasmania
Australia Amarin Investigational Site Lismore New South Wales
Australia Amarin Investigational Site Melbourne Victoria
Australia Amarin Investigational Site Murdoch Western Australia
Australia Amarin Investigational Site Nedlands Western Australia
Australia Amarin Investigational Site Perth Western Australia
Canada Amarin Investigational Site Brampton Ontario
Canada Amarin Investigational Site Collingwood Ontario
Canada Amarin Investigational Site Coquitlam British Columbia
Canada Amarin Investigational Site Corunna Ontario
Canada Amarin Investigational Site Edmonton Alberta
Canada Amarin Investigational Site Laval Quebec
Canada Amarin Investigational Site Montreal Quebec
Canada Amarin Investigational Site Montreal Quebec
Canada Amarin Investigational Site Newmarket Ontario
Canada Amarin Investigational Site Québec
Canada Amarin Investigational Site Québec
Canada Amarin Investigational Site Sarnia Ontario
Canada Amarin Investigational Site Sherbrooke Quebec
Canada Amarin Investigational Site St. Charles-Borromée Quebec
Canada Amarin Investigational Site Strathroy Ontario
Canada Amarin Investigational Site Vancouver British Columbia
Canada Amarin Investigational Site Vancouver British Columbia
India Amarin Investigational Site Bangalore Karnataka
India Amarin Investigational Site Bangalore Karnataka
India Amarin Investigational Site Bangalore Karnataka
India Amarin Investigational Site Chennai Tamil Nadu
India Amarin Investigational Site Coimbatore Tamil Nadu
India Amarin Investigational Site Hyderabad Andhra Pradesh
India Amarin Investigational Site Hyderabad Andhra Pradesh
India Amarin Investigational Site Kottayam Kerala
India Amarin Investigational Site Mumbai Maharashtra
India Amarin Investigational Site Mysore Karnataka
India Amarin Investigational Site Mysore Karnataka
India Amarin Investigational Site Nashik Maharashtra
India Amarin Investigational Site New Delhi Delhi
India Amarin Investigational Site New Delhi Delhi
India Amarin Investigational Site Pune Maharashtra
India Amarin Investigational Site Secunderabad Andhra Pradesh
India Amarin Investigational Site Visakhapatnam Andhra Pradesh
Netherlands Amarin Investigational Site Almelo
Netherlands Amarin Investigational Site Amersfoort
Netherlands Amarin Investigational Site Blaricum
Netherlands Amarin Investigational Site Capelle aan den Ijssel
Netherlands Amarin Investigational Site Den Haag
Netherlands Amarin Investigational Site Den Helder
Netherlands Amarin Investigational Site Deventer
Netherlands Amarin Investigational Site Ede
Netherlands Amarin Investigational Site Eindhoven
Netherlands Amarin Investigational Site Enschede
Netherlands Amarin Investigational Site Goes
Netherlands Amarin Investigational Site Gorinchem
Netherlands Amarin Investigational Site Gouda
Netherlands Amarin Investigational Site Groningen
Netherlands Amarin Investigational Site Haarlem
Netherlands Amarin Investigational Site Harderwijk
Netherlands Amarin Investigational Site Heerenveen
Netherlands Amarin Investigational Site Heerlen
Netherlands Amarin Investigational Site Hoofddorp
Netherlands Amarin Investigational Site Leeuwarden
Netherlands Amarin Investigational Site Leiderdorp
Netherlands Amarin Investigational Site Nijmegen
Netherlands Amarin Investigational Site Roosendaal
Netherlands Amarin Investigational Site Rotterdam
Netherlands Amarin Investigational Site Rotterdam
Netherlands Amarin Investigational Site Rotterdam
Netherlands Amarin Investigational Site s'Hertogenbosch
Netherlands Amarin Investigational Site Schiedam
Netherlands Amarin Investigational Site Sneek
Netherlands Amarin Investigational Site Tilburg
Netherlands Amarin Investigational Site Tilburg
Netherlands Amarin Investigational Site Uden
Netherlands Amarin Investigational Site Veldhoven
Netherlands Amarin Investigational Site Zoetermeer
Netherlands Amarin Investigational Site Zutphen
New Zealand Amarin Investigational Site Christchurch
New Zealand Amarin Investigational Site Dunedin
New Zealand Amarin Investigational Site Hamilton
New Zealand Amarin Investigational Site Hastings
New Zealand Amarin Investigational Site Nelson
New Zealand Amarin Investigational Site New Plymouth
New Zealand Amarin Investigational Site Takapuna Auckland
New Zealand Amarin Investigational Site Takapuna Auckland
New Zealand Amarin Investigational Site Tauranga
New Zealand Amarin Investigational Site Whangarei
Poland Amarin Investigational Site Bialystok
Poland Amarin Investigational Site Bialystok
Poland Amarin Investigational Site Katowice
Poland Amarin Investigational Site Katowice
Poland Amarin Investigational Site Kraków
Poland Amarin Investigational Site Mikolów
Poland Amarin Investigational Site Skierniewice
Poland Amarin Investigational Site Tarnów
Poland Amarin Investigational Site Warszawa
Poland Amarin Investigational Site Warszawa
Poland Amarin Investigational Site Warszawska
Poland Amarin Investigational Site Wroclaw
Poland Amarin Investigational Site Wroclaw
Poland Amarin Investigational Site Zgierz
Romania Amarin Investigational Site Arges
Romania Amarin Investigational Site Braila
Romania Amarin Investigational Site Bucharest
Romania Amarin Investigational Site Bucharest
Romania Amarin Investigational Site Bucharest
Romania Amarin Investigational Site Bucuresti
Romania Amarin Investigational Site Bucuresti
Romania Amarin Investigational Site Bucuresti
Romania Amarin Investigational Site Cluj-Napoca
Romania Amarin Investigational Site Constanta
Romania Amarin Investigational Site Craiova, Dolj
Romania Amarin Investigational Site Iasi
Romania Amarin Investigational Site Maramures
Romania Amarin Investigational Site Mures
Romania Amarin Investigational Site Sibiu
Romania Amarin Investigational Site Târgu Mures
Romania Amarin Investigational Site Timisoara
Russian Federation Amarin Investigational Site Arkhangelsk
Russian Federation Amarin Investigational Site Arkhangelsk
Russian Federation Amarin Investigational Site Arkhangelsk
Russian Federation Amarin Investigational Site Ekaterinburg
Russian Federation Amarin Investigational Site Ekaterinburg
Russian Federation Amarin Investigational Site Kazan
Russian Federation Amarin Investigational Site Kazan
Russian Federation Amarin Investigational Site Kemerovo
Russian Federation Amarin Investigational Site Kemerovo
Russian Federation Amarin Investigational Site Kirovsk, Leningradskaya Region
Russian Federation Amarin Investigational Site Krasnodar
Russian Federation Amarin Investigational Site Moscow
Russian Federation Amarin Investigational Site Moscow
Russian Federation Amarin Investigational Site Moscow
Russian Federation Amarin Investigational Site Moscow
Russian Federation Amarin Investigational Site Moscow
Russian Federation Amarin Investigational Site Moscow
Russian Federation Amarin Investigational Site Moscow
Russian Federation Amarin Investigational Site Moscow
Russian Federation Amarin Investigational Site Moscow
Russian Federation Amarin Investigational Site Moscow
Russian Federation Amarin Investigational Site Moscow
Russian Federation Amarin Investigational Site Nizhny Novgorod
Russian Federation Amarin Investigational Site Novosibirsk
Russian Federation Amarin Investigational Site Novosibirsk
Russian Federation Amarin Investigational Site Novosibirsk
Russian Federation Amarin Investigational Site Petrozavodsk
Russian Federation Amarin Investigational Site Saint-Petersburg
Russian Federation Amarin Investigational Site Saint-Petersburg
Russian Federation Amarin Investigational Site Saint-Petersburg
Russian Federation Amarin Investigational Site Saint-Petersburg
Russian Federation Amarin Investigational Site Saint-Petersburg
Russian Federation Amarin Investigational Site Saint-Petersburg
Russian Federation Amarin Investigational Site Saint-Petersburg
Russian Federation Amarin Investigational Site Saint-Petersburg
Russian Federation Amarin Investigational Site Saint-Petersburg
Russian Federation Amarin Investigational Site Saint-Petersburg
Russian Federation Amarin Investigational Site Saint-Petersburg
Russian Federation Amarin Investigational Site Saint-Petersburg
Russian Federation Amarin Investigational Site Saint-Petersburg
Russian Federation Amarin Investigational Site Saint-Petersburg
Russian Federation Amarin Investigational Site Saint-Petersburg
Russian Federation Amarin Investigational Site Saratov
Russian Federation Amarin Investigational Site Saratov
Russian Federation Amarin Investigational Site Sestroretsk, Saint-Petersburg
Russian Federation Amarin Investigational Site Tomsk
Russian Federation Amarin Investigational Site Tomsk
Russian Federation Amarin Investigational Site Volgograd
Russian Federation Amarin Investigational Site Voronezh
Russian Federation Amarin Investigational Site Voronezh
Russian Federation Amarin Investigational Site Yaroslavl
Russian Federation Amarin Investigational Site Yaroslavl
South Africa Amarin Investigational Site Bellville Western Cape
South Africa Amarin Investigational Site Benoni Gauteng
South Africa Amarin Investigational Site Bloemfontein Freestate
South Africa Amarin Investigational Site Cape Town Western Cape
South Africa Amarin Investigational Site Durban KwaZulu-Natal
South Africa Amarin Investigational Site Durbanville Western Cape
South Africa Amarin Investigational Site Goodwood Western Cape
South Africa Amarin Investigational Site Kraaifontein Western Cape
South Africa Amarin Investigational Site Newlands KwaZulu-Natal
South Africa Amarin Investigational Site Paarl Western Cape
South Africa Amarin Investigational Site Panorama Western Cape
South Africa Amarin Investigational Site Parow Western Cape
South Africa Amarin Investigational Site Pinelands Western Cape
South Africa Amarin Investigational Site Pretoria Gauteng
South Africa Amarin Investigational Site Somerset West Western Cape
South Africa Amarin Investigational Site Soweto Gauteng
South Africa Amarin Investigational Site Witbank Gauteng
South Africa Amarin Investigational Site Worcester Western Cape
Ukraine Amarin Investigational Site Cherkasy
Ukraine Amarin Investigational Site Chernivtsi
Ukraine Amarin Investigational Site Dnipropetrovsk
Ukraine Amarin Investigational Site Dnipropetrovsk
Ukraine Amarin Investigational Site Dnipropetrovsk
Ukraine Amarin Investigational Site Donetsk
Ukraine Amarin Investigational Site Donetsk
Ukraine Amarin Investigational Site Ivano-Frankivsk
Ukraine Amarin Investigational Site Ivano-Frankivsk
Ukraine Amarin Investigational Site Kharkiv
Ukraine Amarin Investigational Site Kharkiv
Ukraine Amarin Investigational Site Kharkiv
Ukraine Amarin Investigational Site Kharkiv
Ukraine Amarin Investigational Site Kyiv
Ukraine Amarin Investigational Site Kyiv
Ukraine Amarin Investigational Site Kyiv
Ukraine Amarin Investigational Site Kyiv
Ukraine Amarin Investigational Site Kyiv
Ukraine Amarin Investigational Site Kyiv
Ukraine Amarin Investigational Site Kyiv
Ukraine Amarin Investigational Site Kyiv
Ukraine Amarin Investigational Site Kyiv
Ukraine Amarin Investigational Site Luhansk
Ukraine Amarin Investigational Site Lutsk
Ukraine Amarin Investigational Site Lutsk Volyn Region
Ukraine Amarin Investigational Site Lviv
Ukraine Amarin Investigational Site Odesa
Ukraine Amarin Investigational Site Odesa
Ukraine Amarin Investigational Site Odesa
Ukraine Amarin Investigational Site Poltava
Ukraine Amarin Investigational Site Ternopil
Ukraine Amarin Investigational Site Uzhgorod
Ukraine Amarin Investigational Site Uzhgorod
Ukraine Amarin Investigational Site Vinnytsya
Ukraine Amarin Investigational Site Vinnytsya
Ukraine Amarin Investigational Site Zaporizhzhia
Ukraine Amarin Investigational Site Zaporizhzhia
Ukraine Amarin Investigational Site Zaporizhzhia
Ukraine Amarin Investigational Site Zaporizhzhia
United States Amarin Investigational Site Addison Illinois
United States Amarin Investigational Site Albany New York
United States Amarin Investigational Site Albuquerque New Mexico
United States Amarin Investigational Site Alexandria Louisiana
United States Amarin Investigational Site Auburn Maine
United States Amarin Investigational Site Aurora Colorado
United States Amarin Investigational Site Austin Texas
United States Amarin Investigational Site Baltimore Maryland
United States Amarin Investigational Site Beaumont Texas
United States Amarin Investigational Site Beaver Pennsylvania
United States Amarin Investigational Site Bend Oregon
United States Amarin Investigational Site Beverly Hills California
United States Amarin Investigational Site Biloxi Mississippi
United States Amarin Investigational Site Birmingham Alabama
United States Amarin Investigational Site Birmingham Alabama
United States Amarin Investigational Site Boston Massachusetts
United States Amarin Investigational Site Boston Massachusetts
United States Amarin Investigational Site Boynton Beach Florida
United States Amarin Investigational Site Bradenton Florida
United States Amarin Investigational Site Bristol Tennessee
United States Amarin Investigational Site Brooklyn New York
United States Amarin Investigational Site Burien Washington
United States Amarin Investigational Site Carrollton Texas
United States Amarin Investigational Site Charlotte North Carolina
United States Amarin Investigational Site Chesterfield Missouri
United States Amarin Investigational Site Chicago Illinois
United States Amarin Investigational Site Chino California
United States Amarin Investigational Site Cincinnati Ohio
United States Amarin Investigational Site Clearwater Florida
United States Amarin Investigational Site Colorado Springs Colorado
United States Amarin Investigational Site Columbia Tennessee
United States Amarin Investigational Site Concord California
United States Amarin Investigational Site Conyers Georgia
United States Amarin Investigational Site Covington Georgia
United States Amarin Investigational Site Cumming Georgia
United States Amarin Investigational Site Dallas Texas
United States Amarin Investigational Site Dayton Ohio
United States Amarin Investigational Site Doylestown Pennsylvania
United States Amarin Investigational Site Durham North Carolina
United States Amarin Investigational Site Edgewater Florida
United States Amarin Investigational Site El Cajon California
United States Amarin Investigational Site Encino California
United States Amarin Investigational Site Eunice Louisiana
United States Amarin Investigational Site Evansville Indiana
United States Amarin Investigational Site Fair Oaks California
United States Amarin Investigational Site Fall River Massachusetts
United States Amarin Investigational Site Falls Church Virginia
United States Amarin Investigational Site Fargo North Dakota
United States Amarin Investigational Site Fleming Island Florida
United States Amarin Investigational Site Florissant Missouri
United States Amarin Investigational Site Fort Lauderdale Florida
United States Amarin Investigational Site Fort Lauderdale Florida
United States Amarin Investigational Site Gastonia North Carolina
United States Amarin Investigational Site Germantown Tennessee
United States Amarin Investigational Site Golden Colorado
United States Amarin Investigational Site Great Neck New York
United States Amarin Investigational Site Guilford Connecticut
United States Amarin Investigational Site Hartford Connecticut
United States Amarin Investigational Site Hastings Nebraska
United States Amarin Investigational Site Hawaiian Gardens California
United States Amarin Investigational Site Henderson Nevada
United States Amarin Investigational Site Honolulu Hawaii
United States Amarin Investigational Site Houston Texas
United States Amarin Investigational Site Houston Texas
United States Amarin Investigational Site Houston Texas
United States Amarin Investigational Site Houston Texas
United States Amarin Investigational Site Houston Texas
United States Amarin Investigational Site Houston Texas
United States Amarin Investigational Site Houston Texas
United States Amarin Investigational Site Huntington West Virginia
United States Amarin Investigational Site Huntsville Alabama
United States Amarin Investigational Site Hurst Texas
United States Amarin Investigational Site Inverness Florida
United States Amarin Investigational Site Iowa City Iowa
United States Amarin Investigational Site Jackson Tennessee
United States Amarin Investigational Site Jacksonville Florida
United States Amarin Investigational Site Jacksonville Florida
United States Amarin Investigational Site Jacksonville Florida
United States Amarin Investigational Site Jacksonville Florida
United States Amarin Investigational Site Jefferson City Missouri
United States Amarin Investigational Site Jersey Shore Pennsylvania
United States Amarin Investigational Site Kansas City Missouri
United States Amarin Investigational Site Kernersville North Carolina
United States Amarin Investigational Site Knoxville Tennessee
United States Amarin Investigational Site Lancaster South Carolina
United States Amarin Investigational Site Lancaster California
United States Amarin Investigational Site Lansing Michigan
United States Amarin Investigational Site Las Vegas Nevada
United States Amarin Investigational Site Lincoln California
United States Amarin Investigational Site Little Rock Arkansas
United States Amarin Investigational Site Liverpool New York
United States Amarin Investigational Site Lorain Ohio
United States Amarin Investigational Site Los Angeles California
United States Amarin Investigational Site Los Angeles California
United States Amarin Investigational Site Los Angeles California
United States Amarin Investigational Site Louisville Kentucky
United States Amarin Investigational Site Lutherville Maryland
United States Amarin Investigational Site Manassas Virginia
United States Amarin Investigational Site Marquette Michigan
United States Amarin Investigational Site Marrero Louisiana
United States Amarin Investigational Site Mesa Arizona
United States Amarin Investigational Site Miami Florida
United States Amarin Investigational Site Miami Florida
United States Amarin Investigational Site Miami Beach Florida
United States Amarin Investigational Site Miami Lakes Florida
United States Amarin Investigational Site Midlothian Virginia
United States Amarin Investigational Site Mobile Alabama
United States Amarin Investigational Site Muscle Shoals Alabama
United States Amarin Investigational Site National City California
United States Amarin Investigational Site New Braunfels Texas
United States Amarin Investigational Site New York New York
United States Amarin Investigational Site New York New York
United States Amarin Investigational Site Newark Delaware
United States Amarin Investigational Site Newport Pennsylvania
United States Amarin Investigational Site Newport News Virginia
United States Amarin Investigational Site Norman Illinois
United States Amarin Investigational Site North Chicago Illinois
United States Amarin Investigational Site North Massapequa New York
United States Amarin Investigational Site Ocala Florida
United States Amarin Investigational Site Ocean City New Jersey
United States Amarin Investigational Site Omaha Nebraska
United States Amarin Investigational Site Omaha Nebraska
United States Amarin Investigational Site Orange California
United States Amarin Investigational Site Orlando Florida
United States Amarin Investigational Site Paramount California
United States Amarin Investigational Site Pembroke Pines Florida
United States Amarin Investigational Site Peoria Illinois
United States Amarin Investigational Site Philadelphia Pennsylvania
United States Amarin Investigational Site Phoenix Arizona
United States Amarin Investigational Site Phoenixville Pennsylvania
United States Amarin Investigational Site Plano Texas
United States Amarin Investigational Site Plantation Florida
United States Amarin Investigational Site Portland Oregon
United States Amarin Investigational Site Raleigh North Carolina
United States Amarin Investigational Site Rapid City South Dakota
United States Amarin Investigational Site Roseville California
United States Amarin Investigational Site Roswell Georgia
United States Amarin Investigational Site Safety Harbor Florida
United States Amarin Investigational Site Saint Cloud Minnesota
United States Amarin Investigational Site Saint Louis Missouri
United States Amarin Investigational Site Saint Peters Missouri
United States Amarin Investigational Site Saint Petersburg Florida
United States Amarin Investigational Site San Antonio Texas
United States Amarin Investigational Site San Antonio Texas
United States Amarin Investigational Site San Diego California
United States Amarin Investigational Site Sandusky Ohio
United States Amarin Investigational Site Sarasota Florida
United States Amarin Investigational Site Sellersville Pennsylvania
United States Amarin Investigational Site Simpsonville South Carolina
United States Amarin Investigational Site Smithtown New York
United States Amarin Investigational Site Smyrna Tennessee
United States Amarin Investigational Site Splendora Texas
United States Amarin Investigational Site Tacoma Washington
United States Amarin Investigational Site Takoma Park Maryland
United States Amarin Investigational Site Tipton Pennsylvania
United States Amarin Investigational Site Tomball Texas
United States Amarin Investigational Site Torrance California
United States Amarin Investigational Site Troy Michigan
United States Amarin Investigational Site Tucson Arizona
United States Amarin Investigational Site Tulsa Oklahoma
United States Amarin Investigational Site Tupelo Mississippi
United States Amarin Investigational Site Ventura California
United States Amarin Investigational Site Vero Beach Florida
United States Amarin Investigational Site Vestal New York
United States Amarin Investigational Site Walnut Creek California
United States Amarin Investigational Site Washington District of Columbia
United States Amarin Investigational Site West Jordan Utah
United States Amarin Investigational Site West Palm Beach Florida
United States Amarin Investigational Site West Seneca New York
United States Amarin Investigational Site Wichita Kansas
United States Amarin Investigational Site Wichita Kansas
United States Amarin Investigational Site Wilmington Delaware
United States Amarin Investigational Site Winfield Illinois
United States Amarin Investigational Site Winston-Salem North Carolina
United States Amarin Investigational Site Wyomissing Pennsylvania
United States Amarin Investigational Site Yardley Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Amarin Pharma Inc.

Countries where clinical trial is conducted

United States,  Australia,  Canada,  India,  Netherlands,  New Zealand,  Poland,  Romania,  Russian Federation,  South Africa,  Ukraine, 

References & Publications (11)

Bhatt DL, Miller M, Brinton EA, Jacobson TA, Steg PG, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Olshansky B, Chung MK, Gibson CM, Giugliano RP, Budoff MJ, Ballantyne CM; REDUCE-IT Investigators. REDUCE-IT USA: Results From the 3 — View Citation

Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Miller M, Tardif JC, Ketchum SB, Doyle RT Jr, Murphy SA, Soni PN, Braeckman RA, Juliano RA, Ballantyne CM; REDUCE-IT Investigators. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017 Mar;40(3):138-148. doi: 10.1002/clc.22692. Epub 2017 Mar 15. — View Citation

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Jiao L, Tardif JC, Gregson J, Pocock SJ, Ballantyne CM; REDUCE-IT Investigators. Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. J Am Coll Cardi — View Citation

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2 — View Citation

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Gregson J, Pocock SJ, Ballantyne CM; REDUCE-IT Investigators. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J — View Citation

Gaba P, Bhatt DL, Giugliano RP, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Tardif JC, Ballantyne CM, Pinto DS, Budoff MJ, Gibson CM. Comparative Reductions in Investigator-Reported and Adjudicated — View Citation

Majithia A, Bhatt DL, Friedman AN, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Budoff M, Preston Mason R, Tardif JC, Boden WE, Ballantyne CM. Benefits of Icosapent Ethyl Across the Range of Kidney — View Citation

Olshansky B, Bhatt DL, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Mehta C, Mukherjee R, Ballantyne CM, Chung MK; REDUCE-IT Investigators. REDUCE-IT INTERIM: accumulation of data across — View Citation

Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE-IT Investigators. Reduction in Revasculariz — View Citation

Singh N, Bhatt DL, Miller M, Steg PG, Brinton EA, Jacobson TA, Jiao L, Tardif JC, Mason RP, Ballantyne CM; REDUCE-IT Investigators. Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT. J Am Coll Cardiol. 2022 Jan 18;79(2):220- — View Citation

Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Icosapent Ethyl — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. The primary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), nonfatal stroke, coronary revascularization, or unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. Total follow-up time of up to approximately 6 years.
Secondary Composite of CV Death, Nonfatal MI (Including Silent MI), or Nonfatal Stroke. The key secondary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. Total follow-up time of up to approximately 6 years.
Secondary Composite of CV Death or Nonfatal MI (Including Silent MI). Number of patients with a first occurrence of any component of the composite of CV death or nonfatal MI (including silent MI) during the follow-up period. Total follow-up time of up to approximately 6 years.
Secondary Fatal or Nonfatal MI (Including Silent MI). Number of patients with a first occurrence of fatal or nonfatal MI (including silent MI) during the follow-up period. Total follow-up time of up to approximately 6 years.
Secondary Non-elective Coronary Revascularization Represented as the Composite of Emergent or Urgent Classifications. Number of patients with a first occurrence of non-elective coronary revascularization represented as the composite of emergent or urgent classifications during the follow-up period. Total follow-up time of up to approximately 6 years.
Secondary CV Death. Number of patients with an occurrence of CV death during the follow-up period. Total follow-up time of up to approximately 6 years.
Secondary Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. Number of patients with a first occurrence of unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. Total follow-up time of up to approximately 6 years.
Secondary Fatal or Nonfatal Stroke. Number of patients with a first occurrence of fatal or nonfatal stroke during the follow-up period. Total follow-up time of up to approximately 6 years.
Secondary Total Mortality, Nonfatal MI (Including Silent MI), or Nonfatal Stroke. Number of patients with a first occurrence of any component of the composite of total mortality, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. Total follow-up time of up to approximately 6 years.
Secondary Total Mortality. Number of patients with an occurrence of death from any cause during the follow-up period. Total follow-up time of up to approximately 6 years.
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)